耐异烟肼结核：一个我们不能再忽视的问题。
Isoniazid-resistant tuberculosis: A problem we can no longer ignore.
机构信息
Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada.
McGill International TB Centre, McGill University, Montreal, Quebec, Canada.
出版信息
PLoS Med. 2020 Jan 21;17(1):e1003023. doi: 10.1371/journal.pmed.1003023. eCollection 2020 Jan.
Abstract
Giorgia Sulis and Madhukar Pai discuss the global distribution, and approaches to diagnosis and treatment, of isoniazid-resistant tuberculosis.
摘要
焦尔贾娅·苏利斯和马杜卡·派讨论了耐异烟肼结核病的全球分布情况，以及诊断和治疗方法。
相似文献
1
Isoniazid-resistant tuberculosis: A problem we can no longer ignore.耐异烟肼结核：一个我们不能再忽视的问题。
PLoS Med. 2020 Jan 21;17(1):e1003023. doi: 10.1371/journal.pmed.1003023. eCollection 2020 Jan.
2
Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data.结核患者异烟肼耐药的流行情况和基因谱：跨国分析的横断面数据。
PLoS Med. 2020 Jan 21;17(1):e1003008. doi: 10.1371/journal.pmed.1003008. eCollection 2020 Jan.
3
Multidrug-resistant and heteroresistant Mycobacterium tuberculosis and associated gene mutations in Ethiopia.埃塞俄比亚耐多药和异耐药结核分枝杆菌及相关基因突变。
Int J Infect Dis. 2015 Oct;39:34-8. doi: 10.1016/j.ijid.2015.06.013. Epub 2015 Jun 25.
4
Prevalence and outcome of isoniazid-monoresistant tuberculosis at a university hospital in Saudi Arabia.沙特阿拉伯一家大学医院异烟肼单耐药结核病的流行率和结局。
Saudi Med J. 2021 Jun;42(6):636-642. doi: 10.15537/smj.2021.42.6.20200832.
5
The impact of improved detection and treatment of isoniazid resistant tuberculosis on prevalence of multi-drug resistant tuberculosis: A modelling study.提高对异烟肼耐药结核病的检测和治疗水平对耐多药结核病流行率的影响：建模研究。
PLoS One. 2019 Jan 24;14(1):e0211355. doi: 10.1371/journal.pone.0211355. eCollection 2019.
6
Molecular detection of multidrug resistance pattern and associated gene mutations in M. tuberculosis isolates from newly diagnosed pulmonary tuberculosis patients in Addis Ababa, Ethiopia.在埃塞俄比亚亚的斯亚贝巴，对新诊断的肺结核患者分离的结核分枝杆菌进行了多药耐药模式和相关基因突变的分子检测。
PLoS One. 2020 Aug 4;15(8):e0236054. doi: 10.1371/journal.pone.0236054. eCollection 2020.
7
Drug-resistance of Mycobacterium tuberculosis in Patras, Greece.希腊帕特雷市结核分枝杆菌的耐药性
Monaldi Arch Chest Dis. 2004 Jan-Mar;61(1):65-70.
8
Global burden of drug-resistant tuberculosis in children: a mathematical modelling study.全球儿童耐多药结核病负担：一项数学建模研究。
Lancet Infect Dis. 2016 Oct;16(10):1193-1201. doi: 10.1016/S1473-3099(16)30132-3. Epub 2016 Jun 21.
9
Time to review treatment of isoniazid-resistant tuberculosis?是时候重新审视耐异烟肼结核病的治疗了吗？
Lancet Infect Dis. 2017 Feb;17(2):127-128. doi: 10.1016/S1473-3099(16)30381-4. Epub 2016 Nov 17.
10
Multidrug- and isoniazid-resistant tuberculosis in three high HIV burden African regions.三个人类免疫缺陷病毒高负担非洲区域的耐多药和异烟肼耐药结核病。
Int J Tuberc Lung Dis. 2013 Aug;17(8):1036-42. doi: 10.5588/ijtld.12.0842.
引用本文的文献
1
Factors associated with unfavourable treatment outcomes among patients with Multidrug-resistant Tuberculosis receiving outpatients care.接受门诊治疗的耐多药结核病患者中与不良治疗结果相关的因素。
Sci Rep. 2025 Aug 4;15(1):28335. doi: 10.1038/s41598-025-13227-5.
2
Drug resistance profile of Mycobacterium tuberculosis complex isolated from pulmonary tuberculosis patients and their household contacts in central Ethiopia.从埃塞俄比亚中部肺结核患者及其家庭接触者中分离出的结核分枝杆菌复合群的耐药谱
BMC Infect Dis. 2025 Jun 20;25(1):806. doi: 10.1186/s12879-025-11220-x.
3
Extrapulmonary tuberculosis in Africa: Molecular analysis of clinical specimens of suspected cases in Northern Ghana.非洲肺外结核病：加纳北部疑似病例临床标本的分子分析
Public Health Chall. 2024 Feb 14;3(1):e160. doi: 10.1002/puh2.160. eCollection 2024 Mar.
4
Sudapyridine (WX-081) inhibits by targeting ATP synthase and upregulating host innate immunity.舒达吡啶（WX - 081）通过靶向ATP合酶和上调宿主固有免疫来发挥抑制作用。
mSphere. 2025 Jun 25;10(6):e0014925. doi: 10.1128/msphere.00149-25. Epub 2025 May 21.
5
The risk of rifampicin-resistant TB after drug-susceptible TB treatment.药物敏感结核病治疗后发生耐利福平结核病的风险。
IJTLD Open. 2025 Mar 12;2(3):173-175. doi: 10.5588/ijtldopen.24.0552. eCollection 2025 Mar.
6
Contribution of direct InhA inhibitors to novel drug regimens in a mouse model of tuberculosis.直接 InhA 抑制剂在结核分枝杆菌感染小鼠模型中新药物方案中的作用。
Antimicrob Agents Chemother. 2024 Nov 6;68(11):e0035724. doi: 10.1128/aac.00357-24. Epub 2024 Sep 30.
7
Drug resistance profiles of clinical isolates by genotype MTBDRplus line probe assay in Zambia: findings and implications.赞比亚采用MTBDRplus线性探针检测法对临床分离株进行耐药谱分析：结果与意义
JAC Antimicrob Resist. 2024 Jul 25;6(4):dlae122. doi: 10.1093/jacamr/dlae122. eCollection 2024 Aug.
8
A 10-year review of isoniazid-resistant TB management in Uzbekistan 2009-2020.2009 - 2020年乌兹别克斯坦耐异烟肼结核病管理的十年回顾
IJTLD Open. 2024 Jul 1;1(7):285-291. doi: 10.5588/ijtldopen.23.0533. eCollection 2024 Jul.
9
The Hidden Epidemic of Isoniazid-Resistant Tuberculosis in South Africa.南非耐异烟肼结核病的隐性流行。
Ann Am Thorac Soc. 2024 Oct;21(10):1391-1397. doi: 10.1513/AnnalsATS.202312-1076OC.
10
Spatial pattern of isoniazid-resistant tuberculosis and its associated factors among a population with migrants in China: a retrospective population-based study.中国流动人口人群中耐异烟肼结核病的空间分布及其相关因素：一项基于人群的回顾性研究。
Front Public Health. 2024 Mar 6;12:1372146. doi: 10.3389/fpubh.2024.1372146. eCollection 2024.
本文引用的文献
1
Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data.结核患者异烟肼耐药的流行情况和基因谱：跨国分析的横断面数据。
PLoS Med. 2020 Jan 21;17(1):e1003008. doi: 10.1371/journal.pmed.1003008. eCollection 2020 Jan.
2
Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.耐药结核病治疗。美国胸科学会/美国疾病控制与预防中心/欧洲呼吸学会/美国感染病学会临床实践指南。
Am J Respir Crit Care Med. 2019 Nov 15;200(10):e93-e142. doi: 10.1164/rccm.201909-1874ST.
3
Tackling drug-resistant tuberculosis: we need a critical synergy of product and process innovations.应对耐药结核病：我们需要产品和流程创新的协同作用。
Int J Tuberc Lung Dis. 2019 Jul 1;23(7):774-782. doi: 10.5588/ijtld.18.0715.
4
Precision medicine and public health interventions: tuberculosis as a model?精准医学与公共卫生干预措施：以结核病为例？
Lancet Public Health. 2019 Aug;4(8):e374. doi: 10.1016/S2468-2667(19)30130-6.
5
Whole genome sequencing of Mycobacterium tuberculosis: current standards and open issues.结核分枝杆菌全基因组测序：当前标准和存在的问题。
Nat Rev Microbiol. 2019 Sep;17(9):533-545. doi: 10.1038/s41579-019-0214-5.
6
What will it take to eliminate drug-resistant tuberculosis?消除耐多药结核病需要什么？
Int J Tuberc Lung Dis. 2019 May 1;23(5):535-546. doi: 10.5588/ijtld.18.0217.
7
Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.不同抗结核药物治疗方案治疗耐多药结核病的比较：一项个体患者数据荟萃分析。
Lancet Respir Med. 2018 Apr;6(4):265-275. doi: 10.1016/S2213-2600(18)30078-X.
8
Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis.一线药物治疗耐异烟肼结核病：系统评价和荟萃分析。
Lancet Infect Dis. 2017 Feb;17(2):223-234. doi: 10.1016/S1473-3099(16)30407-8. Epub 2016 Nov 17.
9
Detection of Isoniazid-, Fluoroquinolone-, Amikacin-, and Kanamycin-Resistant Tuberculosis in an Automated, Multiplexed 10-Color Assay Suitable for Point-of-Care Use.在适用于即时检测的自动化多重十色检测法中检测耐异烟肼、氟喹诺酮、阿米卡星和卡那霉素的结核病
J Clin Microbiol. 2016 Dec 28;55(1):183-198. doi: 10.1128/JCM.01771-16. Print 2017 Jan.
10
Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project.基于人群的结核分枝杆菌分离株对吡嗪酰胺和氟喹诺酮类药物的耐药性：一项多国监测项目的结果
Lancet Infect Dis. 2016 Oct;16(10):1185-1192. doi: 10.1016/S1473-3099(16)30190-6. Epub 2016 Jul 7.
Zotero 插件